Free Trial

Minerva Neurosciences (NERV) 10K Form and Latest SEC Filings 2026

Minerva Neurosciences logo
$5.50 -0.05 (-0.90%)
Closing price 04:00 PM Eastern
Extended Trading
$5.50 0.00 (0.00%)
As of 05:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Minerva Neurosciences SEC Filings & Recent Activity

Minerva Neurosciences (NASDAQ:NERV) has submitted 300+ documents to the U.S. Securities and Exchange Commission (SEC) since 2017. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form 10-Q submitted on May 5, 2026.

Form 4
Minerva Neurosciences, Inc. Reports Ownership Change on Apr. 22, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Minerva Neurosciences Files Current Report on May. 5, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-Q
Minerva Neurosciences Files Quarterly Report on May. 5, 2026

The 10-Q contains Minerva Neurosciences's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

Minerva Neurosciences SEC Filing History

Browse Minerva Neurosciences' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/05/2026 7:30 AM
Minerva Neurosciences (1598646) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/05/2026 7:09 AM
Minerva Neurosciences (1598646) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/23/2026 6:00 AM
Minerva Neurosciences (1598646) Filer
Form DEF 14A
04/23/2026 6:02 AM
Minerva Neurosciences (1598646) Filer
Form DEFA14A
04/23/2026 6:05 AM
Minerva Neurosciences (1598646) Filer
Form ARS
04/22/2026 3:53 PM
Minerva Neurosciences (1598646) Issuer
O'Connor James Joseph (2129698) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/22/2026 3:55 PM
Minerva Neurosciences (1598646) Issuer
O'Connor James Joseph (2129698) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/10/2026 8:20 AM
Minerva Neurosciences (1598646) Filer
Form PRE 14A
04/06/2026 4:07 PM
Minerva Neurosciences (1598646) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/31/2026 4:00 PM
FEDERATED HERMES INSURANCE SERIES (912577) Reporting
Minerva Neurosciences (1598646) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/31/2026 3:57 PM
Federated Hermes Equity Funds (745968) Reporting
Minerva Neurosciences (1598646) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/31/2026 3:57 PM
Federated Hermes Equity Funds (745968) Reporting
Minerva Neurosciences (1598646) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/19/2026 11:15 PM
Minerva Neurosciences (1598646) Filer
Form EFFECT
03/11/2026 8:20 AM
Minerva Neurosciences (1598646) Filer
Form S-3
Registration statement under Securities Act of 1933  
03/11/2026 7:00 AM
Minerva Neurosciences (1598646) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/11/2026 6:07 AM
Minerva Neurosciences (1598646) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/10/2026 4:15 PM
Federated Hermes Equity Funds (745968) Reporting
Minerva Neurosciences (1598646) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/10/2026 4:20 PM
FEDERATED HERMES INSURANCE SERIES (912577) Reporting
Minerva Neurosciences (1598646) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/17/2026 5:12 PM
Logos Global Management LP (1792126) Filed by
Minerva Neurosciences (1598646) Subject
Form SCHEDULE 13G
02/17/2026 7:12 AM
BALYASNY ASSET MANAGEMENT L.P. (1218710) Filed by
Minerva Neurosciences (1598646) Subject
Form SCHEDULE 13G
02/12/2026 8:02 AM
Adage Capital Management, L.P. (1535978) Filed by
Minerva Neurosciences (1598646) Subject
Form SCHEDULE 13G
02/05/2026 1:51 PM
Farallon Capital Partners, L.P. (1175707) Filed by
Minerva Neurosciences (1598646) Subject
Form SCHEDULE 13G/A
02/03/2026 8:00 AM
Minerva Neurosciences (1598646) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/06/2026 11:15 PM
Minerva Neurosciences (1598646) Filer
Form EFFECT
01/06/2026 3:52 PM
Minerva Neurosciences (1598646) Filer
Form 424B3
12/31/2025 3:30 PM
Minerva Neurosciences (1598646) Subject
Vivo Opportunity Fund Holdings, L.P. (1930214) Filed by
Form SCHEDULE 13G
12/30/2025 3:05 PM
Boehringer AG (1984047) Filed by
Minerva Neurosciences (1598646) Subject
Form SCHEDULE 13D/A
12/29/2025 7:29 AM
FEDERATED HERMES, INC. (1056288) Filed by
FEDERATED HERMES, INC. (1056288) Filed by
Minerva Neurosciences (1598646) Subject
Form SCHEDULE 13G
12/23/2025 3:52 PM
Minerva Neurosciences (1598646) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
12/23/2025 3:15 PM
Luthringer Remy (1610384) Reporting
Minerva Neurosciences (1598646) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/23/2025 3:15 PM
Minerva Neurosciences (1598646) Issuer
Race Geoff (1610382) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/23/2025 3:15 PM
Ahlholm Frederick W (1405279) Reporting
Minerva Neurosciences (1598646) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/23/2025 3:15 PM
Minerva Neurosciences (1598646) Issuer
VAN HEEK G JAN (1021040) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/23/2025 3:15 PM
Laghrissi-Thode Fouzia (1642015) Reporting
Minerva Neurosciences (1598646) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/23/2025 3:15 PM
HASLER HANS PETER (1226286) Reporting
Minerva Neurosciences (1598646) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/23/2025 3:15 PM
Kaul Inderjit (2095703) Reporting
Minerva Neurosciences (1598646) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/23/2025 3:15 PM
Kupfer David (1642053) Reporting
Minerva Neurosciences (1598646) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/22/2025 3:05 PM
Minerva Neurosciences (1598646) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/24/2025 3:07 PM
Minerva Neurosciences (1598646) Filer
Form ARS
11/19/2025 7:40 AM
Minerva Neurosciences (1598646) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/18/2025 3:47 PM
Kaul Inderjit (2095703) Reporting
Minerva Neurosciences (1598646) Issuer
Form 3
Initial statement of beneficial ownership of securities  
SpaceX eyes a 1.75 trillion valuation - here's what to know (Ad)

Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.tc pixel

See how to get positioned in SpaceX before the announcement goes public
11/18/2025 3:49 PM
Kaul Inderjit (2095703) Reporting
Minerva Neurosciences (1598646) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/05/2025 6:00 AM
Minerva Neurosciences (1598646) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
10/28/2025 3:39 PM
FEDERATED HERMES, INC. (1056288) Filed by
FEDERATED HERMES, INC. (1056288) Filed by
Minerva Neurosciences (1598646) Subject
Form SCHEDULE 13D
10/21/2025 7:25 PM
Minerva Neurosciences (1598646) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)

Minerva Neurosciences SEC Filings - Frequently Asked Questions

Minerva Neurosciences (NERV) has submitted 300+ filings to the SEC since 2017. You can browse the complete history or filter by form type using the tools above.

Minerva Neurosciences's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results.

The most recent filing was a Form 10-Q submitted on May 5, 2026. This was a quarterly financial update for 2025.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:NERV) was last updated on 5/14/2026 by MarketBeat.com Staff.
From Our Partners